Neuberger Berman Group
RLAY icon

Neuberger Berman Group’s Relay Therapeutics RLAY Stock Holding History

Neuberger Berman Group’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202K Buy
10,822
+774
+8% +$11.2K ﹤0.01% 2177
2026
Q1 		$100K Buy
+10,048
New +$89.9K ﹤0.01% 2075

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Neuberger Berman Group's RLAY Position: Q2 2026 in Review

Neuberger Berman Group increased its Relay Therapeutics (RLAY) stake by 7.7% in Q2 2026, buying an estimated $11.2K and bringing the position to 10,822 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #2177.

Neuberger Berman Group first reported a position in RLAY in Q1 2026 and has held it in 2 quarters since. 260 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Neuberger Berman Group held 10,822 shares of Relay Therapeutics worth $202K as of Q2 2026.
  • Neuberger Berman Group bought 774 Relay Therapeutics shares in Q2 2026, an estimated $11.2K.
  • Relay Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2177 holding.
  • Neuberger Berman Group first reported a position in Relay Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 260 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.